Trial Profile
Efficacy and Safety of Baricitinib in Systemic Sclerosis: a Phase IV, Double-blinded, Controlled Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Cyclophosphamide; Prednisone
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- 01 Apr 2022 New trial record